CDNA
VENTE TOTALE: 267 479 titres (~10 251 571,84 $ US)
- Insiders
- Bickerstaff George, COURNOYER CHRISTINE, Goldberg Michael, Hanna John Walter JR, Valantine Hannah
- Total bought
- —
- Total sold
- $10,251,572
- Last activity
- 2026-08-05
- Last synced
-
2026-08-11 09:46:50
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-10
CDNA delivered a strong Q2 2026 earnings beat (68% EPS surprise) with 52% revenue growth, generating a legitimate positive catalyst, but the ~$10.25M in insider selling immediately post-earnings materially undermines…
The first sentence of the analysis written for CDNA on 2026-08-10 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 67.6% | 67.2% | 63.6% | 65.1% | 67.1% | |
| Ebit Margin | -6.6% | -16.1% | -37.4% | -23.7% | -10.8% | |
| Ebitda Margin | -1.2% | -10.2% | -30.3% | -18.7% | -6.8% | |
| Operating Profit Margin | -6.6% | 12.2% | -72.5% | -24.0% | -10.0% | |
| Pretax Profit Margin | -5.6% | 15.8% | -67.8% | -23.7% | -10.8% | |
| Continuous Operations Profit Margin | -5.6% | 15.7% | -67.9% | -23.8% | -10.3% | |
| Net Profit Margin | -5.6% | 15.7% | -67.9% | -23.8% | -10.3% | |
| Bottom Line Profit Margin | -5.6% | 15.7% | -67.9% | -23.8% | -10.3% | |
| Current Ratio | 2.862 | 3.937 | 4.018 | 5.105 | 5.606 | |
| Quick Ratio | 2.565 | 3.719 | 3.769 | 4.852 | 5.384 | |
| Solvency Ratio | -0.009 | 0.642 | -0.829 | -0.541 | -0.186 | |
| Cash Ratio | 0.728 | 1.283 | 1.053 | 1.184 | 4.508 | |
| Price To Earnings Ratio | -47.100 | 21.410 | -3.390 | -7.924 | -77.085 | |
| Price To Earnings Growth Ratio | 0.336 | -0.167 | -0.023 | -0.055 | -1.623 | |
| Forward Price To Earnings Growth Ratio | 0.336 | -0.167 | -0.023 | -0.055 | -1.623 | |
| Price To Earnings Diluted Ratio | -47.100 | 23.022 | -3.390 | -7.924 | -77.085 | |
| Price To Earnings Diluted Growth Ratio | 0.329 | -0.182 | -0.023 | -0.055 | -1.623 | |
| Price To Book Ratio | 3.312 | 2.986 | 2.469 | 1.412 | 5.100 | |
| Price To Sales Ratio | 2.643 | 3.385 | 2.302 | 1.891 | 8.016 | |
| Price To Free Cash Flow Ratio | 27.795 | 35.796 | -23.352 | -12.273 | -60.069 | |
| Price To Operating Cash Flow Ratio | 23.885 | 29.696 | -35.087 | -24.106 | -123.143 | |
| Debt To Assets Ratio | 0.063 | 0.058 | 0.073 | 0.072 | 0.038 | |
| Debt To Equity Ratio | 0.086 | 0.075 | 0.131 | 0.090 | 0.046 | |
| Debt To Capital Ratio | 0.080 | 0.070 | 0.116 | 0.083 | 0.044 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.363 | 1.298 | 1.786 | 1.260 | 1.216 | |
| Working Capital Turnover Ratio | 1.768 | 1.340 | 1.024 | 0.964 | 1.059 | |
| Operating Cash Flow Ratio | 0.468 | 0.426 | -0.236 | -0.332 | -0.250 | |
| Operating Cash Flow Sales Ratio | 0.111 | 0.114 | -0.066 | -0.078 | -0.065 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.859 | 0.830 | 1.503 | 1.964 | 2.050 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 1.605 | 1.341 | -0.537 | -0.647 | -0.904 | |
| Capital Expenditure Coverage Ratio | 7.108 | 5.868 | -1.990 | -1.037 | -0.952 | |
| Dividend Paid And Capex Coverage Ratio | 7.108 | 5.868 | -1.990 | -1.037 | -0.952 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -207.240 | -30.697 | -7.033 | -9.256 | -101.410 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 67.5% | ▲0.4% | ▲1.4% |
| Ebit Margin | -6.6% | ▲9.5% | ▲12.3% |
| Ebitda Margin | -1.2% | ▲9.0% | ▲12.2% |
| Operating Profit Margin | -6.6% | ▼-18.8% | ▲13.6% |
| Pretax Profit Margin | -5.5% | ▼-21.4% | ▲12.9% |
| Continuous Operations Profit Margin | -5.6% | ▼-21.4% | ▲12.8% |
| Net Profit Margin | -5.6% | ▼-21.4% | ▲12.8% |
| Bottom Line Profit Margin | -5.6% | ▼-21.4% | ▲12.8% |
| Current Ratio | 2.862 | ▼-1.075 | ▼-1.444 |
| Quick Ratio | 2.565 | ▼-1.154 | ▼-1.493 |
| Solvency Ratio | -0.009 | ▼-0.651 | ▲0.176 |
| Cash Ratio | 0.728 | ▼-0.555 | ▼-1.023 |
| Price To Earnings Ratio | -47.100 | ▼-68.510 | ▼-24.282 |
| Price To Earnings Growth Ratio | 0.336 | ▲0.503 | ▲0.643 |
| Forward Price To Earnings Growth Ratio | 0.336 | ▲0.503 | ▲0.643 |
| Price To Earnings Diluted Ratio | -47.100 | ▼-70.121 | ▼-24.605 |
| Price To Earnings Diluted Growth Ratio | 0.329 | ▲0.512 | ▲0.640 |
| Price To Book Ratio | 3.312 | ▲0.327 | ▲0.257 |
| Price To Sales Ratio | 2.643 | ▼-0.742 | ▼-1.004 |
| Price To Free Cash Flow Ratio | 27.795 | ▼-8.001 | ▲34.216 |
| Price To Operating Cash Flow Ratio | 23.885 | ▼-5.811 | ▲49.636 |
| Debt To Assets Ratio | 0.063 | ▲0.006 | ▲0.003 |
| Debt To Equity Ratio | 0.086 | ▲0.011 | ▲0.001 |
| Debt To Capital Ratio | 0.080 | ▲0.010 | ▲0.001 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.363 | ▲0.066 | ▼-0.021 |
| Working Capital Turnover Ratio | 1.768 | ▲0.427 | ▲0.537 |
| Operating Cash Flow Ratio | 0.468 | ▲0.042 | ▲0.453 |
| Operating Cash Flow Sales Ratio | 0.111 | ▼-0.003 | ▲0.108 |
| Free Cash Flow Operating Cash Flow Ratio | 0.859 | ▲0.030 | ▼-0.582 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 1.605 | ▲0.263 | ▲1.433 |
| Capital Expenditure Coverage Ratio | 7.108 | ▲1.240 | ▲5.309 |
| Dividend Paid And Capex Coverage Ratio | 7.108 | ▲1.240 | ▲5.309 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -207.240 | ▼-176.543 | ▼-136.113 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.00B | $1.13B | $645.2M | $608.4M | $2.38B | |
| Enterprise value | $964.7M | $1.04B | $597.2M | $557.5M | $2.05B | |
| EV / Sales | 2.54x | 3.13x | 2.13x | 1.73x | 6.91x | |
| EV / Op. cash flow | 22.95x | 27.43x | -32.48x | -22.09x | -106.19x | |
| EV / Free cash flow | 26.71x | 33.06x | -21.62x | -11.25x | -51.80x | |
| EV / EBITDA | -207.24x | -30.70x | -7.03x | -9.26x | -101.41x | |
| Net debt / EBITDA | 8.43x | 2.54x | 0.56x | 0.85x | 16.19x | |
| Current ratio | 2.86x | 3.94x | 4.02x | 5.11x | 5.61x | |
| Income quality | -1.97x | 0.72x | 0.10x | 0.33x | 0.63x | |
| Graham number | — | $13 | — | — | — | |
| Graham net-net | $2 | $4 | $1 | $5 | $6 | |
| Tax burden | 101.3% | 99.4% | 100.1% | 100.5% | 95.6% | |
| Interest burden | 84.1% | -98.3% | 181.5% | 100.0% | 100.0% | |
| Working capital | $167.3M | $262.5M | $235.6M | $311.9M | $356.1M | |
| Invested capital | $295.3M | $398.9M | $386.8M | $462.7M | $483.3M | |
| Return on assets | -5.2% | 10.7% | -40.8% | -14.1% | -5.4% | |
| Operating ROA | -5.5% | 8.5% | -40.3% | -13.9% | -6.4% | |
| Return on tangible assets | -6.3% | 12.7% | -50.0% | -16.6% | -6.4% | |
| Return on equity | -7.0% | 13.9% | -72.8% | -17.8% | -6.6% | |
| Return on invested capital | -7.6% | 9.9% | -51.5% | -16.3% | -5.8% | |
| Return on capital employed | -7.8% | 10.1% | -52.3% | -16.5% | -6.1% | |
| Earnings yield | -2.1% | 4.7% | -29.5% | -12.6% | -1.3% | |
| Free cash flow yield | 3.6% | 2.8% | -4.3% | -8.1% | -1.7% | |
| Capex / Op. cash flow | 14.1% | 17.0% | -50.3% | -96.4% | -105.0% | |
| Capex / Depreciation | 29.0% | 32.8% | 46.6% | 152.0% | 170.5% | |
| Capex / Sales | 1.6% | 1.9% | 3.3% | 7.6% | 6.8% | |
| SG&A / Sales | 55.3% | 61.6% | 71.8% | 61.0% | 51.4% | |
| R&D / Sales | 18.8% | 21.7% | 29.2% | 28.1% | 25.8% | |
| Stock comp / Sales | 9.2% | 19.9% | 17.5% | 14.5% | 12.2% | |
| Intangibles / Total assets | 17.5% | 16.0% | 18.4% | 14.8% | 15.4% | |
| Days sales outstanding | 41d | 71d | 66d | 75d | 74d | |
| Days payables outstanding | 30d | 26d | 46d | 32d | 50d | |
| Operating cycle | 120d | 136d | 136d | 138d | 138d | |
| Cash conversion cycle | 90d | 110d | 90d | 105d | 88d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-11.1%EV / Sales ▼-18.8%EV / EBITDA ▼-575.1%EV / Op. cash flow ▼-4.475Earnings yield ▼-0.068
Profitability
Return on equity ▼-0.209Return on assets ▼-0.159Return on invested capital ▼-0.175Return on capital employed ▼-0.179Operating ROA ▼-0.141Income quality ▼-2.692Tax burden ▲+0.019
Efficiency
Days sales outstanding ▼-29.680Days payables outstanding ▲+3.992Operating cycle ▼-15.520Cash conversion cycle ▼-19.513Capex / Sales ▼-0.004R&D / Sales ▼-0.029
Balance-sheet strength
Current ratio ▼-1.075Net debt / EBITDA ▲+5.889Working capital ▼-95178000.000Invested capital ▼-103563000.000Intangibles / Total assets ▲+0.015
Change over 5 years
Valuation
Market cap ▼-57.7%EV / Sales ▼-63.3%EV / EBITDA ▼-104.4%EV / Op. cash flow ▲+129.140Earnings yield ▼-0.008
Profitability
Return on equity ▼-0.005Return on assets ▲+0.002Return on invested capital ▼-0.018Return on capital employed ▼-0.017Operating ROA ▲+0.008Income quality ▼-2.598Tax burden ▲+0.057
Efficiency
Days sales outstanding ▼-32.627Days payables outstanding ▼-20.403Operating cycle ▼-17.945Cash conversion cycle ▲+2.459Capex / Sales ▼-0.053R&D / Sales ▼-0.070
Balance-sheet strength
Current ratio ▼-2.744Net debt / EBITDA ▼-7.764Working capital ▼-188776000.000Invested capital ▼-187964000.000Intangibles / Total assets ▲+0.021
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2023-03-06 | Daniel Goldman | Sale (Full) | $1,001 - $15,000 |
| 2021-12-29 | Tom Malinowski | Purchase | $1,001 - $15,000 |
| 2021-03-02 | Tom Malinowski | Purchase | $15,001 - $50,000 |
| 2021-01-11 | Tom Malinowski | Sale (Partial) | $1,001 - $15,000 |
| 2021-01-08 | Tom Malinowski | Sale (Partial) | $1,001 - $15,000 |
| 2021-01-06 | Tom Malinowski | Sale (Partial) | $15,001 - $50,000 |
| 2020-12-23 | Tom Malinowski | Purchase | $1,001 - $15,000 |
| 2020-12-07 | Tom Malinowski | Purchase | $1,001 - $15,000 |
| 2020-11-16 | Tom Malinowski | Purchase | $1,001 - $15,000 |
| 2020-10-09 | Tom Malinowski | Sale (Partial) | $1,001 - $15,000 |
Recent news
- 2026-08-07 CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the award of inducement grants. On August 5, 2026, as an inducement material to acceptance of employment with CareDx, 35 new employees were awarded restricted stock units (RSUs) for an aggregate of 97,090 shares of common stock. With respect to 34 of the new employees, an aggregate of 93,090 of the RSUs will vest o.
- 2026-07-31 CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced that, on July 30, 2026, CareDx granted to James McNally, the Company''s newly appointed Executive Advisor, certain stock awards as an inducement material to Mr. McNally''s employment with CareDx. CareDx granted 15,822 shares of common stock restricted stock units (RSUs) to Mr. McNally. The RSU awards were made pursua.
- 2026-07-31 Why CareDx Stock Jumped Today CareDx is helping to improve outcomes for transplant patients. The health monitor''s non-invasive tests are in high demand.
- 2026-07-30 CareDx, Inc. (CDNA) Q2 2026 Earnings Call Transcript CareDx, Inc. (CDNA) Q2 2026 Earnings Call Transcript
- 2026-07-30 CareDx (CDNA) Beats Q2 Earnings and Revenue Estimates CareDx (CDNA) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.1 per share a year ago.
- 2026-07-30 CareDx Q2 Earnings Call Highlights CareDx NASDAQ: CDNA reported second-quarter 2026 revenue growth of 52% as the transplant diagnostics company expanded testing services, completed the sale of its lab products business and began integrating the recently acquired NavDx specialty oncology platform.
- 2026-07-30 CareDx Announces Second Quarter 2026 Financial Results BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights Revenue of $132 million, an increase of 52% year-over-year Testing Services revenue of $100 million, an increase of 61% year-over-year, and Testing Services volume of approximately 58,000, an increase of 17% year-o.
- 2026-07-23 CareDx (CDNA) Earnings Expected to Grow: Should You Buy? CareDx (CDNA) doesn''t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 2026-07-21 Amova Asset Management Americas Inc. Increases Position in CareDx, Inc. $CDNA Amova Asset Management Americas Inc. raised its holdings in shares of CareDx, Inc. (NASDAQ: CDNA) by 2.0% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,475,126 shares of the company''s stock after purchasing an additional 28,510 shares during the period. Amova Asset
- 2026-07-20 CareDx''s Growth Prospects With Naveris Keep Me Bullish CareDx has a transplant-testing franchise that taps into recurring surveillance demand and has deeper integration into transplant centers. I also think CDNA''s AlloHeme gives them longer-term optionality in post-cell-therapy monitoring. More recently, CDNA sold Lab Products and purchased Naveris. These major strategic M&A deals mean CDNA now has a potential growth engine in oncology.